The potential role of curcumin in prostate cancer: the importance of optimizing pharmacokinetics in clinical studies

被引：19
作者：
Schmidt, Keith T. [1 ]
Figg, William D. [1 ,2 ]
机构：
[1] NCI, Clin Pharmacol Program, Off Clin Director, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
[2] NCI, Mol Pharmacol Sect, Genitourinary Malignancies Branch, Ctr Canc Res,NIH, 9000 Rockville Pike,Bldg 10,Room 5A01, Bethesda, MD 20892 USA
来源：
TRANSLATIONAL CANCER RESEARCH | 2016年 / 5卷
基金：
美国国家卫生研究院;
关键词：
ANDROGEN RECEPTOR; PHASE-II; DOCETAXEL; ANALOGS; NANOPARTICLES; PREDNISONE; ASC-J9(R); GROWTH; ENZALUTAMIDE; MITOXANTRONE;
D O I：
10.21037/tcr.2016.11.04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1107 / S1110
页数：4
相关论文
共 25 条
[1]  
Cheng AL, 2001, ANTICANCER RES, V21, P2895
[2]   Curcumin and cancer: barriers to obtaining a health claim [J].
Devassy, Jessay G. ;
Nwachukwu, Ifeanyi D. ;
Jones, Peter J. H. .
NUTRITION REVIEWS, 2015, 73 (03) :155-165
[3]   Phase II trial of curcumin in patients with advanced pancreatic cancer [J].
Dhillon, Navneet ;
Aggarwal, Bharat B. ;
Newman, Robert A. ;
Wolff, Robert A. ;
Kunnumakkara, Ajaikumar B. ;
Abbruzzese, James L. ;
Ng, Chaan S. ;
Badmaev, Vladimir ;
Kurzrock, Razelle .
CLINICAL CANCER RESEARCH, 2008, 14 (14) :4491-4499
[4]   Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1α signaling [J].
Du, Yuefeng ;
Long, Qingzhi ;
Zhang, Lin ;
Shi, Ying ;
Liu, Xioagang ;
Li, Xudong ;
Guan, Bin ;
Tian, Yanchao ;
Wang, Xinyang ;
Li, Lei ;
He, Dalin .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 47 (06) :2064-2072
[5]   Effect of curcumin on the interaction between androgen receptor and Wnt/beta-catenin in LNCaP xenografts [J].
Hong, Jeong Hee ;
Lee, Gilho ;
Choi, Han Yong .
KOREAN JOURNAL OF UROLOGY, 2015, 56 (09) :656-665
[6]   Molecular mechanisms of curcumin and its semisynthetic analogues in prostate cancer prevention and treatment [J].
Jordan, Brian C. ;
Mock, Charlotta D. ;
Thilagavathi, Ramasamy ;
Selvam, Chelliah .
LIFE SCIENCES, 2016, 152 :135-144
[7]   Differential Androgen Deprivation Therapies with Anti-androgens Casodex/Bicalutamide or MDV3100/Enzalutamide versus Anti-androgen Receptor ASC-J9® Lead to Promotion versus Suppression of Prostate Cancer Metastasis [J].
Lin, Tzu-Hua ;
Lee, Soo Ok ;
Niu, Yuanjie ;
Xu, Defeng ;
Liang, Liang ;
Li, Lei ;
Yeh, Shauh-Der ;
Fujimoto, Naohiro ;
Yeh, Shuyuan ;
Chang, Chawnshang .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2013, 288 (27) :19359-19369
[8]   The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study [J].
Mahammedi, Hakim ;
Planchat, Eloise ;
Pouget, Melanie ;
Durando, Xavier ;
Cure, Herve ;
Guy, Laurent ;
Van-Praagh, Isabelle ;
Savareux, Laurent ;
Atger, Marc ;
Bayet-Robert, Mathilde ;
Gadea, Emilie ;
Abrial, Catherine ;
Thivat, Emilie ;
Chollet, Philippe ;
Eymard, Jean-Christophe .
ONCOLOGY, 2016, 90 (02) :69-78
[9]   Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents [J].
Ohtsu, H ;
Xiao, ZY ;
Ishida, J ;
Nagai, M ;
Wang, HK ;
Itokawa, H ;
Su, CY ;
Shih, C ;
Chiang, TY ;
Chang, E ;
Lee, YF ;
Tsai, MY ;
Chang, CS ;
Lee, KH .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (23) :5037-5042
[10]   Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [J].
Petrylak, DP ;
Tangen, CM ;
Hussain, MHA ;
Lara, PN,J ;
Jones, JA ;
Taplin, ME ;
Burch, PA ;
Berry, D ;
Moinpour, C ;
Kohli, M ;
Benson, MC ;
Small, EJ ;
Raghavan, D ;
Crawford, ED .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (15) :1513-1520
123